Join to View Full Profile
Dana-Farber Cancer InstiM 430Boston, MA 02115
Phone+1 617-632-4768
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Meyerson, MD is a board certified pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is a Professor of Pathology at Dana-Farber Cancer Institute.
Education & Training
Mass General Brigham/Massachusetts General HospitalResidency, Pathology-Anatomic and Clinical, 1994 - 1997
Harvard Medical SchoolClass of 1993
Certifications & Licensure
MA State Medical License 1996 - 2025
American Board of Pathology Clinical Pathology
Publications & Presentations
PubMed
- 1 citationsResolution of ring chromosomes, Robertsonian translocations, and complex structural variants from long-read sequencing and telomere-to-telomere assembly.Yulia Mostovoy, Philip M Boone, Yongqing Huang, Kiran V Garimella, Kar-Tong Tan
American Journal of Human Genetics. 2024-12-05 - An essential role for Cmtr2 in mammalian embryonic development.Alena V Yermalovich, Zarin Mohsenin, Mitzy Cowdin, Bruno Giotti, Akansha Gupta
Developmental Biology. 2024-12-01 - 2 citationsDiscovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran-Active KAT6AB Inhibitor.Antonius Ter Laak, Roman C Hillig, Steven J Ferrara, Daniel Korr, Naomi Barak
Journal of Medicinal Chemistry. 2024-11-14
Press Mentions
Dana-Farber Experts Present Innovative Cancer Studies at the 2025 AACR Annual MeetingApril 26th, 2025- Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025
- Dana-Farber Researchers Receive AACR 2025 Scientific Achievement AwardsApril 14th, 2025
- Join now to see all
Grant Support
- Lung Adenocarcinoma: From Genome Alterations to Therapeutic DiscoveryDANA-FARBER CANCER INST2015–2028
